SEC Form 10-Q Summary
Filing identity: The supplied filing is for Zeta Acquisition Corp. II, not Whitehawk Therapeutics, Inc. Investors should verify the issuer before relying on this summary. The report covers the quarter and six months ended June 30, 2015, and was filed August 13, 2015.
Business Context and Reporting Period
Zeta Acquisition Corp. II was a Delaware blank-check and shell company formed to identify and complete a business combination. It has generated no revenue or operating cash flow since inception and had not identified or entered into discussions with a potential target as of the filing date. The company reported 5,000,000 common shares outstanding and classified itself as a smaller reporting company and emerging growth company.
Financial Results and Position
| Metric | Three Months Ended June 30, 2015 | Six Months Ended June 30, 2015 | Comparable 2014 Period |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| General and administrative expense | $5,103 | $9,065 | $5,307 and $9,445, respectively |
| Interest expense | $2,169 | $4,022 | $1,645 and $3,273, respectively |
| Net loss | $(7,272) | $(13,087) | $(6,952) and $(12,718), respectively |
| Net loss per share | $(0.00) | $(0.00) | $(0.00) |
At June 30, 2015, cash and cash equivalents were $10,095, compared with $5,263 at December 31, 2014. Current liabilities were $178,223, including $145,000 of stockholder notes payable, $28,024 of accrued interest, $3,200 of accrued expenses and $1,999 of accounts payable. Stockholders’ deficit was $168,128.
For the six months ended June 30, 2015, operating activities used $15,168 of cash, compared with $1,715 used in the prior-year period. Financing activities provided $20,000 from stockholder loans, compared with no financing proceeds in the 2014 period. The resulting increase in cash was $4,832, compared with a decrease of $1,715 in 2014. No investing activity was reported.
Material Changes Versus the Prior Comparable Period
- Six-month net loss increased by $369, or approximately 3%, to $13,087, despite a $380 decline in general and administrative expense.
- Six-month interest expense increased by $749, or approximately 23%, to $4,022.
- Operating cash outflow increased substantially, from $1,715 to $15,168.
- Cash increased because the company received $20,000 of additional unsecured stockholder loans bearing interest at 6% and payable on demand.
- Accrued interest increased from $24,002 at December 31, 2014 to $28,024 at June 30, 2015.
Guidance, Outlook, Risks and Unusual Items
Management plans to continue searching for a suitable acquisition candidate and expects to incur costs for SEC reporting and acquisition investigations. It expects to fund these activities through existing cash, deferred service-provider fees, stockholder or management loans, or additional investment. No assurance was provided that additional funding will be available.
The filing states that substantial doubt exists regarding the company’s ability to continue as a going concern. The company has nominal assets, accumulated losses of $218,128 since inception, no revenue, and liabilities substantially exceeding cash. Continued operations depend on additional financing and the successful identification and completion of a business combination or reverse merger.
Stockholder notes payable totaled $145,000 at June 30, 2015. The company also disclosed approximately $74,200 of deferred tax assets, fully offset by a valuation allowance. It reported no material litigation, off-balance-sheet arrangements, unregistered equity sales, or defaults upon senior securities. Management concluded that disclosure controls and procedures were effective as of June 30, 2015, with no material changes in internal control.
Investor Verification Priorities
- Verify that the filing belongs to Zeta Acquisition Corp. II rather than Whitehawk Therapeutics, Inc.
- Confirm the company’s current legal identity, trading status, and any subsequent business combination or reverse merger.
- Review the availability and terms of related-party financing, including the $145,000 of stockholder notes and $28,024 of accrued interest.
- Assess the company’s ability to fund operations given $10,095 of cash against $178,223 of current liabilities.
- Determine whether management identified a target, obtained new financing, or resolved the going-concern uncertainty after June 30, 2015.